Advisory Committees

banner
TIA’s advisory committees provide strategic advice on the following areas: pharmaceutical commercialisation, product development capabilities and specific therapeutic research areas. The five advisory committees are:    “Virtual Pharma” Pharmaceutical Development Network (PDN), Queensland (QLD) node, Clinical Trial Infrastructure (CTI), Biopharmaceutical Biomaterial and Medical Devices committee (BBMD) and the Cell and Gene Therapy Committee (C&GT). Each committee is chaired by a leader in the field that appoints members for their respective committee. Every committee meets twice a year to discuss strategic direction in the specific field. In addition, funding allocation TIA's recently announced project, NCRIS 2013, will be overseen by its NCRIS Expert Advisory Committee (NEAC).

“Virtual Pharma”/ Pharmaceutical Development Network (PDN)
Dr. George Morstyn is the chair of the Virtual Pharma. Dr Morstyn is applying his experience in Translational Medicine in the academic commercial interface. He is on the Boards of Proacta (based in Auckland and San Diego developing cancer therapy), Chemgenex, AMT (gene therapy), and Neuprotect. Dr Morstyn is Deputy Chairman of the $1 Billion Parkville Comprehensive Cancer Centre, he is a Director and Chairman of the scientific advisory Board of Symbio (Japan based biotech developing drugs for cancer treatment) and Chairman of GBS Ventures. Dr Morstyn also advises The Walter and Eliza Hall Institute on commercialization.  His interest in Translational Research dates back to 1979 when he commenced a PhD with Professor Don Metcalf. Dr Morstyn became head of the Clinical Program of the Ludwig Institute for Cancer Research in Melbourne. He was principal investigator of the earliest studies of G-CSF, GM-CSF and IL-4. Dr Morstyn joined Amgen in 1991 as an advisor, later became VP of Medical and Clinical Affairs, then Chief Medical Officer and in 1999 Senior Vice President of Development.
Through the expertise available in the Virtual Pharma committee, advice can be given on all aspects of pharmaceutical development and commercialisation. For information regarding members of this committee, please follow this link.


Queensland node
Professor Peter Andrews is the chair of the QLD node strategic committee. He is an eminent scientist and bio-entrepreneur and was appointed as Queensland’s first Chief Scientist in 2003, retiring in December 2010. Professor Andrews completed his PhD in the pharmacological applications of quantum chemistry at the University of Melbourne in 1969. He has since led multidisciplinary scientific teams at several Australian universities, and has been at the forefront of the development of the Australian biotechnology industry as a founder or board member of more than 10 scientific companies. In 2000, together with Professor John Mattick AO, Professor Andrews founded Queensland’s Institute for Molecular Bioscience – the first of several world-class biomedical research institutes established under the Queensland government’s Smart State Strategy. He is a Fellow of the Royal Australian Chemical Institute, the Australian Academy of Technological Sciences and Engineering, and the Australian Institute of Company Directors. In 2004 he was appointed an Officer of the Order of Australia.

The QLD node provides a facilitated product development pathway to assist university-based life sciences discovery researchers to develop their inventions from the discovery laboratory and into the clinical development stages. This committee operates on two levels, the strategic committee chaired by Professor Andrews and the operational committee which is chaired by Professor Maree Smith. Please click on following links for members of the strategic committee and the executive committee.


Clinical Trial Infrastructure (CTI)
Professor Judith Whitworth is the chair on the CTI committee. Professor Whitworth is an Emeritus Professor at the Australian National University where she was previously Director of the John Curtin Schools of Medical Research. She is a Fellow of the Australian Academy of Technological Sciences and Engineering, the Royal Australasian College of Physicians, and the Australian Institute of Company Directors. Professor Whitworth has chaired the Medical Research Committee of the NHMRC and is a Past-President of the Australian Society for Medical Research, and the High Blood Pressure Research Council of Australia as well as an Honorary Life Member of the Australian and New Zealand Society of Nephrology. Previous appointments include Commonwealth Chief Medical Officer of Australia, Chair of the WHO Global Advisory Committee on Health Research, and Professor of Medicine at St George Hospital, UNSW. Professor Whitworth was made a Companion in the Order of Australia in 2001, for service to the advancement of academic medicine and as a major contributor to research policy and medical research administration in Australia and internationally, and was also a recipient of the Centenary Medal. She was Telstra ACT Business Woman of the Year 2002 and in 2004 was ACT Australian of the Year. Other awards include the Curtin Medal, the Kincaid Smith Medal, the Florey Medal and the RACP Medal.

For information regarding members of the CTI committee, please click on following link.


Biopharmaceutical Biomaterial and Medical Devices committee (BBMD)
Professor Bryan Williams is the chair of the BBMD committee. Professor Williams is Director of the Monash Institute of Medical Research, where he also leads the Centre for Cancer Research. He has a distinguished research career spanning over 35 years in the areas of innate immunity and cancer biology. Professor Williams is Chairman of the Board of Directors of Marshall Edwards Inc., a NASDAQ-listed company involved in the clinical development of cancer therapeutics, and is Chairman of the Board of BioGrid Australia Ltd. He is the Australian Director for Pacific Edge Pty Ltd, a cancer diagnostics company, and is a Member of the Board of Directors for Cancer Trials Australia. He is also a Member of the Board of Trustees of the Hope Funds for Cancer Research, and serves as a Member of the Consultative Council of the Victorian Cancer Agency. He is currently Chair of the Selection Panel for the Victorian Premier's Award for Health and Medical Research.Members of this committee can be found on this link.


Cell and Gene Therapy Committee (C&GT)
Professor Ian Gust is the chair of the C&GT committee. Professor Gust is a medical virologist with advanced training in pathology and infectious diseases, who has led large public and private sector research organizations and been an advisor to Government, Industry and International Organizations. He completed a combined science/ medicine degree at the University of Melbourne (1964) and undertook post graduate training at the London School of Hygiene and Tropical Medicine and the Regional Virus Laboratory, Glasgow (1967-1969). Professor Gust worked as a Medical Virologist at Fairfield Hospital for Communicable Diseases where he founded and was the founding Director of the Burnet Institute. He was invited to become the R&D Director at CSL Ltd in 1990 and has served as a non-executive director of ASX listed Biota Holdings P/L, and the VC funded unlisted Promics P/L and Opal Therapeutics P/L which were spun out of the Universities of Queensland and Melbourne, respectively.Professor Gust has also been a member of the Scientific Advisory Boards of Opal Therapeutics P/L, Virax P/L, Chemgenix and the US based Genocea P/L and is a member of the Boards of The International AIDS Vaccine Initiative (New York), The Paediatric Vaccine Initiative (Seoul) and the Australian International Health Institute (Melbourne), was a founding member of the Board of Trustees of the International Vaccine Institute (Seoul) and has recently been appointed Chair of the Bio 21 cluster.

For information regarding members of the CTI committee, please click on the following link.

NCRIS Expert Advisory Committee (NEAC)
Dr George Morstyn, Professor Judith Whitworth, Professor Nicos Nicola of the Walter and Eliza Hall Institute and Professor Ross McKinnon of the Flinders Centre for Innovation in Cancer join Dr Stewart Hay in this committee.  The Australian Government will provide funding for the renewal of the National Collaborative Research Infrastructure Strategy (NCRIS) from 2013–14 to 2014–15. As part of NCRIS 2013, TIA will implement a $7M 'carryover funding' strategy to provide financial support to the most critical aspects of the capability network. The implementation of this new project follows an extensive consultation process that engaged consortium stakeholders and State Government representatives.